Experimental pill combo shows promise for Hard-to-Treat cancers
NCT ID NCT01534598
First seen Nov 21, 2025 · Last updated Apr 23, 2026 · Updated 14 times
Summary
This early-phase trial tested two experimental drugs taken by mouth—FdCyd and THU—in 59 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the combination could control tumor growth. Participants took the drugs for three days in the first two weeks of each 21-day cycle, continuing as long as their cancer stayed stable and side effects were manageable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
Penn State
Hershey, Pennsylvania, 17033, United States
-
UC Davis Cancer Center
Sacramento, California, 95817, United States
-
USC Norris Cancer Center
Los Angeles, California, 90033, United States
-
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.